Medtronic completes SPR Therapeutics acquisition to expand non-opioid pain care

Corporate ActionProduct / Tech
โดย Simply Wall St·Read original
Summary · why it matters

Medtronic has completed its acquisition of SPR Therapeutics, adding a minimally invasive, non-opioid peripheral nerve stimulation system to its pain therapy portfolio. The deal brings the SPRINT system under Medtronic's umbrella, giving the company a short-term therapy option that can sit alongside its existing spinal cord and implanted neuromodulation devices for chronic and acute pain. This move expands Medtronic's presence in earlier-stage pain interventions and aligns with a broader healthcare push to reduce reliance on opioid medications. Integration of the smaller, focused platform will require careful commercial execution, pricing decisions, and reimbursement alignment to ensure clinically appropriate use. The acquisition also positions Medtronic as a more comprehensive partner for pain clinics versus large device peers such as Abbott and Boston Scientific.

Impact on stocks 3

Robotics & Physical AI▲ · 1 stocks
Medtronic PLC
MDT
▲ PositiveTechnologyrelevance

Acquisition adds SPRINT non-opioid PNS system to Medtronic's pain therapy portfolio, expanding into earlier-stage interventions.

Biotech & Genomic Medicine▼ · 1 stocks
Abbott Laboratories
ABT
▼ NegativeCompetitionrelevance

Medtronic's acquisition strengthens its pain therapy portfolio, increasing competitive pressure on Abbott.

Brain-Computer Interface▼ · 1 stocks
Boston Scientific Corp
BSX
▼ NegativeCompetitionrelevance

Medtronic's expanded portfolio makes it a more comprehensive partner for pain clinics, challenging Boston Scientific.

Off-coverage companies 1

SPR TherapeuticsPrivate▲ Positive
Capitalrelevance

SPR Therapeutics is acquired by Medtronic, providing an exit for its investors.

© 2026 MarketDXNews